Milestone Scientific Expands CompuFlo® Epidural System Footprint with InfiniSurg, LLC in New Jersey
MWN-AI** Summary
Milestone Scientific Inc. has made significant strides in expanding its CompuFlo® Epidural System footprint by collaborating with InfiniSurg, LLC, an ambulatory surgery center located in New Jersey. Announced on April 1, 2025, this partnership allows the renowned anesthesiologist, Dr. Roman Kosiborod, to incorporate the innovative CompuFlo® system into his practice at InfiniSurg. With over two decades of experience in interventional pain management, Dr. Kosiborod specializes in minimally invasive spinal procedures and emphasizes the importance of patient safety and procedural effectiveness.
The CompuFlo® Epidural System utilizes Dynamic Pressure Sensing Technology to provide real-time feedback during epidural placements. This innovative approach minimizes the risk of complications such as dural puncture, enhancing both clinician confidence and patient safety. Dr. Kosiborod expressed his enthusiasm for the integration of this technology, highlighting its potential to improve procedural outcomes in outpatient settings.
InfiniSurg, known for its patient-centric approach and commitment to utilizing advanced technologies in surgical care, believes that adopting the CompuFlo® system is a critical step towards optimizing patient results. Milestone Scientific's Chairman and Interim CEO, Neal Goldman, celebrated this development, seeing it as a testament to the company's strategic aim of making CompuFlo® a new standard for epidural procedures across healthcare institutions.
Milestone Scientific, a leading developer of computerized drug delivery instruments, focuses on creating technologies that enhance injection precision and patient comfort. Through partnerships like this, the company aims to further validate and expand the reach of its groundbreaking technologies within the medical community.
MWN-AI** Analysis
Milestone Scientific Inc. (NYSE: MLSS) recently expanding its CompuFlo® Epidural System footprint with InfiniSurg, LLC, signifies a pivotal moment for the company and could present significant opportunities for investors. The integration of CompuFlo® into InfiniSurg's clinical practices underscores the growing acceptance of advanced medical technologies in outpatient surgery, reflecting broader trends towards patient-centric care and operational efficiencies.
Dr. Roman Kosiborod, a seasoned anesthesiologist at InfiniSurg, has endorsed the CompuFlo® Epidural System for its real-time feedback capabilities, highlighting its potential to improve procedure accuracy and patient outcomes. With patient safety increasingly at the forefront of medical practice, products that offer enhanced precision—such as those employing Dynamic Pressure Sensing Technology®—are likely to gain traction among healthcare providers. This development aligns with Milestone’s strategic objective to position CompuFlo® as a new standard of care for epidural procedures, potentially driving future revenue growth.
As Milestone Scientific's technologies receive adoption from reputable institutions like InfiniSurg, there is inherent value for investors to consider. The integration of this technology could lead to a wider acceptance within the healthcare community, creating additional revenue streams through increased sales of CompuFlo® systems and related consumable products.
However, potential investors should remain mindful of the risks highlighted in Milestone’s recent communications, including regulatory hurdles, market competition, and broader economic conditions that may affect healthcare spending. A keen analysis of these factors against the backdrop of advancing technology adoption is vital.
In conclusion, while investing in Milestone Scientific offers promising upside potential due to its innovative offerings and strategic partnerships, a balanced consideration of the risks involved is essential for making informed investment decisions. Keeping an eye on future developments and market penetration will be critical in evaluating Milestone’s financial trajectory as it continues to innovate within the medical technology space.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
ROSELAND, N.J., April 01, 2025 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE: MLSS) , a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced that InfiniSurg, LLC, a premier ambulatory surgery center based in New Jersey, has incorporated the CompuFlo® Epidural System into its clinical practice. The device will be utilized by Roman Kosiborod, DO, a highly experienced anesthesiologist and pain management physician. This order was received through Milestone’s distributor, Axial Biologics.
Dr. Kosiborod brings over two decades of expertise in interventional pain management and ambulatory anesthesia. He is the Managing Director at Comprehensive Pain Management and Anesthesia and has held leadership positions across multiple healthcare organizations. Dr. Kosiborod specializes in minimally invasive procedures for spinal pain, including epidural injections, medial branch blocks, radiofrequency ablation, and spinal cord stimulation.
“We are excited to integrate the CompuFlo® Epidural System at InfiniSurg,” stated Dr. Kosiborod. “The system’s objective pressure sensing technology provides real-time feedback, which enhances procedural confidence and may reduce complications associated with traditional epidural placement. This technology aligns with our mission of delivering safer and more effective care to our patients.”
InfiniSurg, LLC is recognized for its patient-centric approach and commitment to innovation in outpatient surgical care. The addition of CompuFlo® reflects InfiniSurg’s focus on leveraging advanced technologies to optimize outcomes and procedural safety.
Neal Goldman, Chairman and Interim Chief Executive Officer of Milestone Scientific, commented, “We are pleased to welcome Dr. Kosiborod and InfiniSurg to the growing number of institutions adopting our CompuFlo® Epidural System. This further validates our technology's value proposition and supports our broader strategy to establish CompuFlo® as the new standard of care for epidural procedures.”
The CompuFlo® Epidural System is designed to precisely identify the epidural space using Dynamic Pressure Sensing Technology®, potentially reducing the risk of dural puncture and other complications. The technology provides both visual and audible feedback to aid clinicians in needle placement, improving procedural efficiency and patient safety.
About Milestone Scientific Inc.
Milestone Scientific Inc. (MLSS), a technology focused medical research and development company that patents, designs and develops innovative injection technologies and instruments for medical and dental applications. Milestone Scientific’s computer-controlled systems are designed to make injections precise, efficient and increase the overall patient comfort and safety. Their proprietary DPS Dynamic Pressure Sensing Technology ® instruments is the platform to advance the development of next-generation devices, regulating flow rate and monitoring pressure from the tip of the needle, through platform extensions of subcutaneous drug delivery, including local anesthetic. To learn more, view the MLSS brand video or visit milestonescientific.com .
Safe Harbor Statement
This press release contains forward-looking statements regarding the timing and financial impact of Milestone's ability to implement its business plan, expected revenues, timing of regulatory approvals and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions, future business decisions and regulatory developments, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone's control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone's periodic filings with the Securities and Exchange Commission, including without limitation, Milestone's Annual Report for the year ended December 31, 2023 . The forward-looking statements in this press release are based upon management's reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.
Contact:
Crescendo Communications, LLC
Email: mlss@crescendo-ir.com
Tel: 212-671-1020
FAQ**
How does the integration of the CompuFlo® Epidural System by InfiniSurg impact the market position of Milestone Scientific Inc. (MLSS) in the medical technology sector?
What are the expected financial implications for Milestone Scientific Inc. (MLSS) following the adoption of the CompuFlo® Epidural System by reputable institutions like InfiniSurg, LLC?
In what ways does the adoption of the CompuFlo® Epidural System enhance patient safety and procedural efficiency compared to traditional techniques, as noted by Milestone Scientific Inc. (MLSS)?
What strategies is Milestone Scientific Inc. (MLSS) employing to increase market penetration for the CompuFlo® Epidural System amidst competitive pressures in the healthcare technology landscape?
**MWN-AI FAQ is based on asking OpenAI questions about Milestone Scientific Inc. (NYSE: MLSS).
NASDAQ: MLSS
MLSS Trading
-1.69% G/L:
$0.28 Last:
12,460 Volume:
$0.2826 Open:
